ライフサイエンスコーパス: oncological

1 This indicates that oncological activity may be based on several mechanisms.

2 ement are critical to ensure both safety and oncological adequacy.

3 nctional outcome, anastomotic leak rate, and oncological adequacy.

4 Despite theoretical oncological advantages associated with AFA-PD and eviden

5 systems and, in doing so, contribute to both oncological and clinical NLP research.

6 c breast surgery (OPBS) were to evaluate the oncological and cosmetic outcomes of OPBS.

7 Long-term oncological and functional outcome data are necessary to

8 Lack of uniform PLND, devoid of long-term oncological and functional outcome data are still issues

9 We investigated the oncological and functional outcomes of neoadjuvant chemo

10 mors or tumors in solitary kidneys with good oncological and functional outcomes.

11 th 10,071 individuals across 14 countries in oncological and haematological settings.

12 and feasible surgical option with comparable oncological and improved renal function outcomes compare

13 duced RF irradiations will be beneficial for oncological and nephrological applications, in which the

14 neurologist because of their prominent neuro-oncological and neuro-developmental consequences.

15 centre, retrospective cohort study including oncological and obstetric data from 134 pregnant patient

16 to enable informed decision-making regarding oncological and reconstructive treatment options.

17 treatment of T1b and T2 renal mass, focusing oncological and renal functional outcomes reported in th

18 improves the clinical predictability of the oncological and toxicological results.

19 Demographic, operative, oncological, and 3-month complication data were collecte

20 to precisely determine and compare surgical, oncological, and breast reconstruction outcomes, includi

21 ta about patient demographics and operative, oncological, and complication details were collected bef

22 unicable diseases, including cardiovascular, oncological, and respiratory illnesses.

23 CA-2) antibody, its frequency, and clinical, oncological, and serological associations.

24 d ~8,000 compounds, including compounds with oncological annotations, as well as FDA-approved drugs,

25 eon's perspective on sentinel node and other oncological applications and on the surgical value of nu

26 rognosis of deep learning technique in neuro-oncological applications for better individualized treat

27 adoption beyond dermatology and a few other oncological applications in which a fiber optic can be t

28 Covering oncological applications, and after a brief history of t

29 he surgical, pathological, radiological, and oncological approaches used to treat this disease, but t

30 tinct cytotoxic agents currently used in the oncological armamentarium mediate their clinical benefit

31 apy continues to evolve as a mainstay of the oncological armamentarium, research and innovation in ra

32 58 (59%) of 98 patients for whom results of oncological assessments were available had tumours, most

33 (18)fluorodeoxyglucose uptake and aggressive oncological behavior.

34 s of LKB1 (KL) in cells specifies aggressive oncological behaviour.

35 the importance of striking a balance between oncological benefit and surgical risk.

36 cult LLRs require technical expertise and an oncological benefit can only be achieved in expert cente

37 e after nCRT according to CROSS regimen, the oncological benefit of immediate surgery in cCR is topic

38 -art glioma treatment aims to maximise neuro-oncological benefit while minimising losses in quality o

39 standardization is the only way to obtain an oncological benefit with this type of resection, and man

40 scopy, and can therefore probably provide an oncological benefit.

41 apy in HPV-driven PSCC might provide greater oncological benefits than standard chemotherapy.

42 operative technique that is associated with oncological benefits.

43 c radical cystectomy to identify its role in oncological bladder surgery.

44 lenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospita

45 Additional obstacles include the cost of oncological care, poor infrastructure, and the scarcity

46 ere prospectively registered at the regional oncological center.

47 Pancreatic cancer is a major oncological challenge due to its aggressive growth and m

48 illustrate the surgical, nephrological, and oncological challenges of this uncommon but important co

49 Although the oncological changes associated with intermittent ADT are

50 ces among all 3 groups regarding general and oncological characteristics and functional parameters on

51 silica scaffold retained significantly more oncological characters than those cultured on the conven

52 Consequently, PRP could have relevant oncological clinical applications for the treatment of a

53 ncreasingly feature in next-generation neuro-oncological clinical trials to deliver repurposed and ex

54 ous cancers, and inhibitors are currently in oncological clinical trials.

55 ur diagnosis; (iii) exclusion of other neuro-oncological complications; and (iv) at least one of the

56 Thus, the oncological concept of somatic loss of heterozygosity le

57 of fluid within the Douglas pouch raised the oncological concern.

58 otein, a biomarker for the onset of multiple oncological conditions, especially bladder cancer.

59 patients with a solitary kidney can achieve oncological control as well as renal function preservati

60 surgery in penile cancer has shown that good oncological control can be gained by 2 mm margins that a

61 mpectomy for breast cancer aims at achieving oncological control with maximal tissue preservation, th

62 s, including safety, functional results, and oncological control, continue to be reported as the tech

63 rectum, and although this provides excellent oncological control, it is associated with morbidity and

64 roaches allow exploitation of high-dimension oncological data in research and development of precisio

65 m the TCGA-HNSC dataset for enhancing future oncological decision support for Head and Neck Squamous

66 assessed the main demographic, clinical, and oncological determinants of survival in the subgroup of

67 ntion to clinical features and demographics, oncological diagnosis, conditioning regimens, neurologic

68 raphic (e.g. age, gender) nor clinical (e.g. oncological diagnosis, type of BMT, time of stroke after

69 Adult patients with oncological disease scheduled for elective port implanta

70 europsychiatric as well as immunological and oncological diseases makes them attractive targets for p

71 Background: Early detection of oncological diseases such as pancreatic ductal adenocarc

72 a major characteristic of cardiovascular and oncological diseases, and many therapies are therefore t

73 nnate immune response could be useful in non-oncological diseases.

74 ic targets for autoimmune, inflammatory, and oncological diseases.

75 shown therapeutic potential in treating non-oncological diseases.

76 ing PARP inhibitors for the treatment of non-oncological diseases.

77 ning increasing traction in the treatment of oncological diseases; however, many clinical failures ha

78 in particular, for systemic applications in oncological disorders.

79 ivity with cardiovascular, neurological, and oncological disorders.

80 E is a valuable alternative to TTE regarding oncological doctrine and overall survival.

81 wledge into an improved, metastasis-oriented oncological drug development strategy is needed to thwar

82 is one of the common targets considered for oncological drug development.

83 Augmenting NK-cell function with oncological drugs could improve NK-cell-based immunother

84 understanding drug-induced cardiotoxicity of oncological drugs that may manifest as contractile and e

85 of patient experience in the development of oncological drugs.

86 ach are still to be refined for clinical and oncological effectiveness and safety.

87 Oncological effectiveness of ablative techniques is enco

88 g-term cardioprotection without compromising oncological efficacy in doxorubicin-treated children wit

89 resent state of the literature regarding the oncological efficacy of minimally invasive radical cyste

90 eoadjuvant therapy and local excision showed oncological equivalence to major resection (HR = 1.12, P

91 With recent long-term oncological equivalence to radical nephrectomy and renal

92 n tomography/computed tomography imaging for oncological evaluation.

93 ts with bladder cancer and to understand key oncological events in the evolution of this disease.

94 anguage processing can be used as a tool for oncological evidence-based research and quality improvem

95 ive, single-center, observational study 1003 oncological examinations (918 patients, mean age 57.8+/-

96 The primary end point was a composite of oncological factors indicating an adequate surgical rese

97 uld be restricted to patients with favorable oncological factors.

98 orbidity and mortality, together with a high oncological feasibility and hypertrophic efficacy.

99 x proteins (NMPs) have been identified as an oncological "fingerprint" for bladder, renal, and prosta

100 l design, which will lead to more comparable oncological, functional and quality of life outcomes.

101 periment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative.

102 The large-scale Collaborative Oncological Gene-environment Study (COGS) presents new f

103 array, iCOGS, developed by the Collaborative Oncological Gene-environment Study (COGS).

104 ment involving four consortia (Collaborative Oncological Gene-environment Study, COGS) and used a cus

105 studies genotyped through the Collaborative Oncological Gene-environment Study.

106 The data indicate that the KL oncological genotype imposes a metabolic vulnerability r

107 t in the Web-based ROGY (Registration System Oncological Gynecology).

108 adjustment disorder in adults with cancer in oncological, haematological, and palliative-care setting

109 in patients with cancer, including those in oncological, haematological, and palliative-care setting

110 Data on demographics, oncological history and comorbidities, COVID-19 diagnosi

111 The oncological hub-and-spoke program did not work adequatel

112 Oncological hub-and-spoke program was planned in 29 depa

113 About 70% of the patients had oncological illness.

114 anoprobes have shown tremendous potential in oncological imaging owing to the high sensitivity and sp

115 tween 1965 and 2009 evaluating the long-term oncological impact of AL were identified by an electroni

116 However, the oncological impacts of a minimally invasive approach to

117 , which, with few exceptions, are mainly for oncological indications and directed against only a hand

118 are mainly being developed and marketed for oncological indications and diseases, such as idiopathic

119 ibitors are currently in clinical trials for oncological indications, and the current results indicat

120 nd discusses the utility of aFP for treating oncological indications.

121 that this poor outcome is due to an inherent oncological inferiority of the traditional abdominoperin

122 , changes in network topology in response to oncological interventions, particularly tumor resection,

123 Excluded were nonsurgical oncological interventions.

124 vide evidence for the strong need for psycho-oncological interventions.

125 assessment criteria for patients with neuro-oncological malignancies undergoing immunotherapy is the

126 tening complications in patients with hemato-oncological malignancies, and early diagnosis is crucial

127 ising area of therapy in patients with neuro-oncological malignancies.

128 how this technique will or will not improve oncological management in our patients.

129 of some differences in short-term surrogate oncological markers, LCR was not inferior to OCR in dire

130 Our results suggest that a close oncological monitoring of patients with BRCA2 mutations

131 ethality an innovative approach toward unmet oncological needs.

132 cies in proteostasis lead to many metabolic, oncological, neurodegenerative, and cardiovascular disor

133 inically important disease models, including oncological, neurological, and cardiovascular diseases.

134 quency of complications without compromising oncological or cosmetic outcomes of the reconstructed br

135 al risk score which is highly predictive for oncological outcome (P < 0.0001).

136 The role of anastomotic leakage in oncological outcome after colorectal cancer surgery is s

137 d by next-generation sequencing (NGS) on the oncological outcome after resection of colorectal liver

138 .9% vs 31.1%, P= 0.007) and a trend to worse oncological outcome compared with ODP.

139 Oncological outcome data is presently lacking.

140 g fecal urgency and incontinence), and three oncological outcome domains (including long-term surviva

141 The aim of this study was to evaluate oncological outcome for patients with and without anasto

142 bidity is common and its impact on long-term oncological outcome is unclear.

143 ABO blood system influences the oncological outcome of recipients undergoing LT for HCC.

144 The oncological outcome of these methods has not been previo

145 Long-term oncological outcome results are needed to establish the

146 Oncological outcome was assessed using Kaplan-Meier esti

147 The most predictive parameters for poor oncological outcome were alterations in the SMAD family

148 e therapy translates into improved long-term oncological outcome, is appropriate.

149 ts with low rectal cancer, thereby improving oncological outcome.

150 Oncological Outcomes after Clinical Complete Response in

151 sis providing compelling evidence that worse oncological outcomes after curative rectal cancer resect

152 The aim of this study was to compare oncological outcomes after minimally invasive distal pan

153 lly selected patients can lead to acceptable oncological outcomes and better quality of life.

154 l lesions with high accuracy and can improve oncological outcomes and fertility preservation of women

155 is as effective as open surgery in terms of oncological outcomes and preservation of QoL.

156 s have also declined such that morbidity and oncological outcomes are comparable to open partial neph

157 ort-term morbidity, mortality, and long-term oncological outcomes are negatively influenced by the oc

158 New data on intermediate and long-term oncological outcomes are now available.

159 ts in I/R injury, regenerative capacity, and oncological outcomes await confirmatory studies in human

160 es, postoperative complications, and initial oncological outcomes between groups.

161 d statistically insignificant differences in oncological outcomes between intermittent and continuous

162 The purpose of this study was to compare oncological outcomes between laparoscopic nephroureterec

163 of the watch-and-wait approach by comparing oncological outcomes between patients managed by watch a

164 ted worldwide, after trials reported similar oncological outcomes compared with open surgery.

165 ce data regarding intermediate and long term oncological outcomes following MIRC, and most reported s

166 The purpose of this study is to evaluate oncological outcomes for breast cancer patients with T1-

167 tion (LLR) and open liver resection (OLR) on oncological outcomes for colorectal cancer liver metasta

168 study aims to report short-term clinical and oncological outcomes from the international transanal To

169 No large-scale studies with long-term oncological outcomes have been published.

170 as associated with comparable short-term and oncological outcomes in comparison with ODP.

171 Given the potential for hope to alter oncological outcomes in patients with cancer and the opp

172 PMRT was not associated with improved oncological outcomes in patients with T1-2 breast cancer

173 be performed with good short and medium term oncological outcomes in selected patients.

174 verse effect of the laparoscopic approach on oncological outcomes in terms of margins or survival, ad

175 Oncological outcomes in these cases were superior for th

176 ly, obesity is also associated with improved oncological outcomes in this cancer.

177 onse following surgery and how it relates to oncological outcomes is one potential area, and is revie

178 Furthermore, its effect on oncological outcomes is unknown.

179 study aims to compare the perioperative and oncological outcomes of laparoscopic and open liver rese

180 vealed that surgeons have concerns about the oncological outcomes of MIDP for PDAC.

181 nsufficient evidence regarding the long-term oncological outcomes of MIRC.

182 , P53, and survivin and the association with oncological outcomes of patients treated by radical cyst

183 The aim of this study is to evaluate the oncological outcomes of robotic total mesorectal excisio

184 weeks following RCT has no influence on the oncological outcomes of T3/T4 rectal cancers.

185 Low rectal cancer oncological outcomes remain a global challenge, evidence

186 al therapy trials are encouraging, long-term oncological outcomes remain to be elucidated.

187 n associated with less morbidity and similar oncological outcomes to open liver resection for colorec

188 ch to colon cancer surgery may offer similar oncological outcomes to Open with potentially less morbi

189 Although a thorough evaluation of oncological outcomes was not possible, the rate of margi

190 Oncological outcomes were comparable and in concordance

191 Short- and long-term oncological outcomes were comparable at a medium follow-

192 and a shorter hospital stay with comparable oncological outcomes when compared with open liver resec

193 copically or percutaneously offers excellent oncological outcomes with single-session therapy.

194 uated (i) the impact of tumor enucleation on oncological outcomes, (ii) the effect of pretherapeutic

195 ic ablative radiotherapy (SABR) on survival, oncological outcomes, toxicity, and quality of life in p

196 tion, and Female Sexual Function Index), and oncological outcomes.

197 tive window and ultimately improve long-term oncological outcomes.

198 The primary endpoints were oncological outcomes.

199 he potential to improve overall surgical and oncological outcomes.

200 ence of compromise to early and intermediate oncological outcomes.

201 ort perioperative, functional and short-term oncological outcomes.

202 g such surgeries had equivalence in terms of oncological outcomes.

203 es, with similar spillage rates and mid-term oncological outcomes.

204 elayed for 6(-12) weeks without jeopardizing oncological outcomes.

205 must be considered in light of the possible oncological outcomes.

206 rative resection of stage II OCC may improve oncological outcomes.

207 gher detection rates translate into improved oncological outcomes.

208 lored treatment approach to further optimize oncological outcomes.

209 ded the incidence of anastomotic leakage and oncological outcomes.

210 ction preservation without affecting initial oncological outcomes.

211 in short-term (pathological) and long-term (oncological) outcomes of radical prostatectomy.

212 of healthcare systems to better protect the oncological path seems a priority.

213 and Mycoses Study Group criteria) in hemato-oncological patients were identified.

214 iable and effective option to provide future oncological patients with better-quality treatment optio

215 accuracy for the diagnosis of IFI in hemato-oncological patients.

216 BG assays for the diagnosis of IFI in hemato-oncological patients.

217 a potential role for DFO in the treatment of oncological patients.

218 llosis (IPA) has dire consequences in hemato-oncological patients.

219 NN) to elucidate its clinical implication in oncological perspectives.

220 Radiomics features extracted from oncological PET images are currently under intense scrut

221 he extent to which radiomics parameters from oncological PET vary in response to manual contouring va

222 he course of progression, leading to several oncological phenomena that are hard to explain with a tr

223 se inhibitors and monoclonal antibodies into oncological practice has opened a new paradigm for treat

224 ded lymph node dissection based on tenets of oncological principles and acceptable short-term oncolog

225 iffering not only in technical approach, but oncological principles as well.

226 to 2-[18F]fluoro-2-deoxyglucose (FDG) as an oncological probe in cultured PC-3 human prostate cancer

227 e risk of port site metastases following uro-oncological procedures.

228 at certain such fusions could be involved in oncological process in AML, and provide a new source to

229 amers as a new drug class to block important oncological processes.

230 bidity and mortality, and similar short-term oncological quality compared to OE.

231 resection guidance with the aim of enabling oncological radical surgery and improvement of patient o

232 identify patients who should be referred for oncological radicalization with hemicolectomy.

233 tures should be considered an indication for oncological radicalization.

234 penia (patients treated for hematological or oncological reasons who are at risk of bleeding), and ch

235 the use of this technology in head and neck oncological reconstruction will be the effect of radioth

236 study, we describe the TERT hypermethylated oncological region (THOR), a 433-bp genomic region encom

237 hypermethylation of the TERT hypermethylated oncological region (THOR).

238 hypermethylation in the TERT hypermethylated oncological region was detected in three tumors.

239 ed progress is made with applying NLP toward oncological research, incremental gains will lead to lar

240 mproved diagnosis and therapy, especially in oncological research.

241 and treatment remain at the leading edge of oncological research.

242 telligence in molecular cancer pathology and oncological research.

243 ndpoints were the safety and adequacy of the oncological resection criteria.

244 ional lymph nodes (MRLNs) precludes curative oncological resection or liver transplantation for chola

245 mapping were performed during open standard oncological resection.

246 n system exists for mandibular defects after oncological resection.

247 he open and transanal approaches may improve oncological resection.

248 mours (NETs) of 1-2 cm in size by performing oncological resections is increasing, but the rarity of

249 s, by improving the accuracy and outcomes of oncological resections.

250 with a particular focus on postoperative and oncological results and on functional outcomes.

251 ospective or retrospective studies reporting oncological results for intervals longer or shorter than

252 partial nephrectomy also provides equivalent oncological results for larger renal tumors including th

253 cal techniques, clinical outcomes, and early oncological results of RAMIE.

254 cancers by ELAPE did not improve short-term oncological results, when compared with conventional APE

255 es in demography, tumor characteristics, and oncological results.

256 rioperative morbidity and mortality and good oncological results.

257 s clear, but there is some concern about the oncological risk.

258 lipotransfer as well as begin to address its oncological risks.

259 ation to the possibility of respecting basic oncological rules and the expertise of the center.

260 ic flexure resection were analyzed to assess oncological safety as well as early and medium-term outc

261 averted permanent colostomy without loss of oncological safety at 3 years.

262 ow include nipple-sparing mastectomy but its oncological safety is still controversial.

263 e need for a randomized trial to confirm the oncological safety of MIDP.

264 These data supports the oncological safety of TPIAT as valuable alternative to p

265 Access to high-quality oncological services remains variable; however, cost of

266 trives to establish a model of excellence in oncological services.

267 ely limit the utility of nanomedicine in the oncological setting.

268 ommendations by authoritative urological and oncological societies regarding the use of intermittent

269 issue that has never been discussed from the oncological standpoint.

270 an serve as a point of comparison for future oncological studies at similar institutions.

271 inimally invasive, precision and intelligent oncological surgery after the rapid development of minim

272 Specialized approaches combining oncological surgery and plastic surgery techniques are c

273 imally invasive techniques into the realm of oncological surgery are hindered by lack of accurate vis

274 geons rigorously adhere to the principles of oncological surgery.

275 A 56-question survey regarding the oncological surgical activity in Italy during the COVID-

276 A careful oncological surveillance pretransplant as well as posttr

277 ls, has been proposed as a compelling immune-oncological target.

278 urthermore, SMC2 represents a new target for oncological therapeutic intervention.

279 elial tumors and prevent the infiltration of oncological therapies into the bulk of the malignancy.

280 mmune checkpoint blockade has revolutionized oncological therapies, and its remarkable success has sp

281 lized as hematological, rheumatological, and oncological therapies, but recent developments are ident

282 h surgical and non-surgical first-line neuro-oncological therapies.

283 ompounds in food should not adversely affect oncological therapy but rather could successfully aid on

284 Nine patients responded to immunotherapy or oncological therapy, but neurological relapses, without

285 rome development, 17 of 33 patients received oncological treatment (nine also immunotherapy), 10 immu

286 al therapy but rather could successfully aid oncological treatment by regulating the quantities of th

287 The future of oncological treatment lies in personalized medicine with

288 Radiotherapy is a primary oncological treatment modality that also damages normal

289 on 29 indicators encompassing brain-directed oncological treatment, surgery, whole-brain radiotherapy

290 ences in functional outcomes following neuro-oncological treatment, we review mounting evidence demon

291 t might be the key to unlocking a new era of oncological treatments associated with a reduced propens

292 vivo, in the selection and planning of neuro-oncological treatments.

293 of solid tumors in the development of modern oncological treatments.

294 r tumors of 7 cm or less provides equivalent oncological tumor control to radical nephrectomy with ma

295 ically mutated genes associated with diverse oncological types to colorectal and breast cancers throu

296 Beyond the emerging field of oncological ultrasound molecular imaging, the recent sig

297 latively high ratio of exon 4-excluded neuro-oncological ventral antigen 1 (Nova1(-4)) and intron 2-r

298 The neuro-oncological ventral antigen 2 (NOVA2) protein is a major

299 adenylation element binding factor and neuro-oncological ventral antigen to specific aspects of synap

300 T) in lesion detection and classification in oncological whole-body examinations and to investigate r